For Immediate Release
Contact: Mary DeLucco
Breast Cancer Action
415.243.9301 xt 16
Katrina Kahl
Breast Cancer Action
415.243.9301 xt 19
San Francisco, CA—Breast Cancer Action (BCA) today applauded the recommendation by a Food & Drug Administration [...]
READ MORE
For Immediate Release
Contact: Mary DeLucco
Breast Cancer Action
415.243.9301 xt 16
Katrina Kahl
Breast Cancer Action
415.243.9301 xt 19
San Francisco, CA—Breast Cancer Action (BCA) today called on the Food & Drug Administration to deny biotech co [...]
READ MORE
For Immediate Release
Contact: Mary DeLucco
Breast Cancer Action
415.243.9301 xt 16
San Francisco, CA—Breast Cancer Action said that today’s action by the U.S. Food & Drug Administration warning about the risks that certain anemia drugs pose to [...]
READ MORE
For Immediate Release
Contact: Mary DeLucco
Breast Cancer Action
415.243.9301 xt 16
Katrina Kahl
Breast Cancer Action
415.243.9301 xt 19
San Francisco—Breast Cancer Action (BCA) said today that a new study that suggests that the chemotherapy drug T [...]
READ MORE
For Immediate Release
Contact: Mary DeLucco
Breast Cancer Action
(415) 243-9301 ext. 16
Katrina Kahl
Breast Cancer
(415) 243-9301 ext. 19
San Francisco—Breast Cancer Action (BCA) today launched its annual Think Before You Pink campaign with a new f [...]
READ MORE
For Immediate Release
Contact: Mary DeLucco
Breast Cancer Action
(415) 243-9301 ext. 16
San Francisco—Breast Cancer Action (BCA) opposes today’s recommendation by a U.S. Food and Drug Administration (FDA) advisory panel to approve the use of raloxifene ( [...]
READ MORE
For Immediate Release
Contact: Mary DeLucco
Breast Cancer Action
(415) 243-9301 ext. 16
San Francisco, CA—Breast Cancer Action (BCA) said today it is not surprised that a new National Cancer Institute study finds that a diet high in vegetables, f [...]
READ MORE
For Immediate Release:
Contact: Mary DeLucco
Breast Cancer Action
(415) 243-9301 ext. 16
San Francisco, CA—Breast Cancer Action (BCA) today expressed grave concerns about two new studies that purport to justify the exorbitantly high price of breast ca [...]
READ MORE
For Immediate Release
Contact: Mary DeLucco
Breast Cancer Action
(415) 243-9301 ext. 16
San Francisco, CA—Breast Cancer Action (BCA) (www. bcaction.org) announced today its support for the National Cancer Institute’s decision not to go ahead with the P-4 [...]
READ MORE
For Immediate Release
Contact: Mary DeLucco
Breast Cancer Action
(415) 243-9301 ext. 16
Breast Cancer Action Demands FDA Reform
San Francisco, CA—Breast Cancer Action (BCA), a national grassroots education and advocacy organization, announced today t [...]
READ MORE
On February 6, 2007, the Food and Drug Administration (FDA) approved the MammaPrint test, a genetic test that aims to predict whether a woman diagnosed with breast cancer will have a recurrence of the disease within 5 to 10 years of the initial diagnosis [...]
READ MORE